BJH - volume 3, issue 3, september 2012
E. Del Biondo MD, H. De Raeve MD, PhD, G. Huysmans MD, K. Hendrickx MD, E. Wouters MD, P. Vandenberghe MD, PhD, P. Meeus MD
The coincidence of a Janus Kinase 2 (JAK2) V617F positive myeloproliferative neoplasm (MPN) and a BCR-ABL1 positive chronic myeloid leukaemia (CML) is rare. We present a patient whose bone marrow and peripheral blood showed typical features of essential thrombocytemia (ET). However, the normalisation of the white blood cell (WBC) count after therapy with imatinib for a gastrointestinal stromal tumour (GIST) suggests that an underlying CML was masked, as witnessed by the very low levels of BCR-ABL1 at the haematological diagnosis. The question remains if this is a case of two separate myeloid malignancies or a secondary event (BCR-ABL1 fusion) in a primary JAK2 V617F + ET.
(BELG J HEMATOL 2012:3:105–107)
Read moreBJH - volume 3, issue 2, june 2012
M. Igala MD, B. Bailly MD, M.F. Dehou MD, S. Goldman MD, PhD, I. Vierasu MD, O. Pradier MD, PhD, A. Kentos MD, PhD, D. Bron MD, PhD
Mantle-cell lymphoma (MCL), located in the central nervous system (CNS) was first described some twenty years ago. It is a rare lymphoma usually diagnosed in the context of a resistant or recurring illness. We report the case of a patient in whom bilateral exophthalmia and palpebral ptosis were the first manifestations of a MCL with retro-orbital and meningeal infiltration.
(BELG J HEMATOL 2012;3:59–61)
Read more
Top
